ES8601700A1 - Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre - Google Patents

Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre

Info

Publication number
ES8601700A1
ES8601700A1 ES538802A ES538802A ES8601700A1 ES 8601700 A1 ES8601700 A1 ES 8601700A1 ES 538802 A ES538802 A ES 538802A ES 538802 A ES538802 A ES 538802A ES 8601700 A1 ES8601700 A1 ES 8601700A1
Authority
ES
Spain
Prior art keywords
plasma
heat treatment
compositions obtained
instance
fractions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES538802A
Other languages
English (en)
Other versions
ES538802A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23490802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8601700(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of ES538802A0 publication Critical patent/ES538802A0/es
Publication of ES8601700A1 publication Critical patent/ES8601700A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/12—Microwaves
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

METODO PARA TRATAR UN CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE. COMPRENDE: LIOFILIZAR UN CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE, SEGUIDO DE CALENTAMIENTO DEL CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE A UNA TEMPERATURA PREDETERMINADA DE 60C, DURANTE UN PERIODO DE TIEMPO PARA CONVERTIR EN NO INFECCIOSO AL VIRUS DE LA HEPATITIS NO DE TIPO A, AL VIRUS DE LA HEPATITIS NO DE TIPO B, A UN VIRUS RELACIONADO CON EL CITOMEGALOVIRUS DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA (AIDS) O AL VIRUS EPTSTEIN-BARR, PRESENTES EN EL CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE. SE EMPLEA UN CONCENTRADO ESENCIALMENTE EXENTO DE LOS FACTORES II, VII, X, XII Y XIII O SUS FORMAS ACTIVAS, QUE TIENE UNA RELACION DE UNIDADES ANTIHEMOFIILICAS DE CUALQUIER ENZIMA DE COAGULACION DE LA SANGRE DE 10:1 A 500:1, Y DONDE EL FACTOR ANTIHEMOFILICO ESTA PURIFICADO HASTA UNA ACTIVIDAD POR PESO UNITARIO DE PROTEINA MAYOR QUE LA CONCENTRACION DEL FACTOR EN EL PLASMA HUMANO NORMAL.
ES538802A 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre Expired ES8601700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06377863 US4456590B2 (en) 1981-11-02 1982-05-13 Heat treatment of lyphilized blood clotting factor viii concentrate

Publications (2)

Publication Number Publication Date
ES538802A0 ES538802A0 (es) 1985-11-01
ES8601700A1 true ES8601700A1 (es) 1985-11-01

Family

ID=23490802

Family Applications (5)

Application Number Title Priority Date Filing Date
ES522310A Granted ES522310A0 (es) 1982-05-13 1983-05-12 Un metodo de tratar una composicion sustancialmente seca que incluye factor viii de plasma sanguineo.
ES535745A Granted ES535745A0 (es) 1982-05-13 1984-09-07 Un metodo de producir una vacuna para la hepatitis
ES538803A Granted ES538803A0 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado de fibrinogeno
ES538802A Expired ES8601700A1 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre
ES538801A Expired ES8601699A1 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor viii de coagulacion de la sangre

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES522310A Granted ES522310A0 (es) 1982-05-13 1983-05-12 Un metodo de tratar una composicion sustancialmente seca que incluye factor viii de plasma sanguineo.
ES535745A Granted ES535745A0 (es) 1982-05-13 1984-09-07 Un metodo de producir una vacuna para la hepatitis
ES538803A Granted ES538803A0 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado de fibrinogeno

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES538801A Expired ES8601699A1 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor viii de coagulacion de la sangre

Country Status (19)

Country Link
US (1) US4456590B2 (es)
EP (2) EP0094611B1 (es)
JP (1) JPS58213721A (es)
AR (1) AR230186A1 (es)
AT (1) AT392905B (es)
AU (3) AU554282B2 (es)
BE (1) BE896724A (es)
BR (1) BR8302504A (es)
CA (1) CA1203165A (es)
CH (1) CH665125A5 (es)
DE (3) DE171506T1 (es)
DK (1) DK171796B1 (es)
ES (5) ES522310A0 (es)
FR (1) FR2526660B1 (es)
GB (2) GB2120254B (es)
IE (1) IE55008B1 (es)
LU (1) LU84804A1 (es)
MX (1) MX172861B (es)
ZA (1) ZA833315B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4994438A (en) * 1981-11-02 1991-02-19 Cedars Sinai Medical Center Heat treatment of lyophilized plasma fractions
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
ZA838856B (en) * 1982-12-02 1984-07-25 Usv Pharma Corp Hepatitis b and non-a-non-b-safe biological products
US4615886A (en) * 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT385657B (de) * 1984-03-09 1988-05-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
DE3587351T3 (de) * 1984-03-23 1998-04-16 Baxter Int Hämoglobin mit reduziertem virusrisiko und dessen herstellung.
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
NL8401066A (nl) * 1984-04-04 1985-11-01 Stichting Centraal Lab Werkwijze ter bereiding van preparaten, die de humorale en cellulaire immuunreaktiviteit vergroten.
US5185160A (en) * 1984-06-21 1993-02-09 Prp, Inc. Platelet membrane microvesicles
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
AT390001B (de) * 1984-09-28 1990-03-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
AT390373B (de) * 1984-10-02 1990-04-25 Schwab & Co Gmbh Verfahren zur pasteurisation von plasmaproteinen bzw. von plasmaproteinfraktionen
ATE52922T1 (de) * 1985-08-05 1990-06-15 Immuno Ag Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren.
CA1276563C (en) * 1985-09-30 1990-11-20 Stanley E. Charm High temperature, short time heating system and method of sterilizing heat-sensitive biological fluids
EP0225581A3 (en) * 1985-11-30 1989-05-24 Green Cross Corporation Method for the heat-treatment of immunoglobulins and immunoglobulin product
DK595285D0 (da) * 1985-12-20 1985-12-20 Nordisk Gentofte Injicerbart og varmebehandet igg-praeparat og fremgangsmaade til fremstilling af samme
DK155886D0 (da) * 1986-04-04 1986-04-04 Bo Arne Hofmann Vaccine og fremgangsmaade til fremstilling af denne
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
US5099002A (en) * 1987-05-15 1992-03-24 University Of Southern California Sequential improved method for treatment of human blood-clotting factor products
US5097018A (en) * 1988-05-12 1992-03-17 University Of Southern California Sequential heat treatment of blood-clotting factor products
US5118795A (en) * 1987-05-15 1992-06-02 University Of Southern California Sequential heat treatment of blood-clotting factor products
AU2251288A (en) * 1987-05-15 1988-12-06 Alan I. Rubinstein Sequential improved method for treatment of human blood- clotting factor products
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US4861867A (en) * 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
EP0378208B2 (en) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Production method for protein-containing composition
US5332578A (en) * 1989-04-14 1994-07-26 Prp, Inc. Platelet membrane microparticles
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
JPH06166634A (ja) * 1992-12-01 1994-06-14 Green Cross Corp:The プラスミノーゲン含有組成物の製造方法
AU6653094A (en) * 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4404625C2 (de) * 1994-02-14 1996-10-17 Ludwig Dr Baumgartner Verfahren zur Inaktivierung thermolabiler Viren in biologischem Material unter Beibehaltung der kollagenen Eigenschaften
US20030143518A1 (en) * 1994-11-18 2003-07-31 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method of drying blood plasma
DE4441167C1 (de) * 1994-11-18 1996-03-14 Fraunhofer Ges Forschung Verfahren zur Trocknung von Blutplasma
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
US5837519A (en) * 1996-11-21 1998-11-17 Bayer Corporation Dry-heat viral inactivation under controlled moisture conditions
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
FR2857267B1 (fr) 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
RU2413532C2 (ru) 2005-07-29 2011-03-10 Зольвай Фармасьютиклз Гмбх Способ получения стерилизованного порошкообразного панкреатина
FR2894830B1 (fr) 2005-12-19 2008-04-04 Lab Francais Du Fractionnement Procede d'inactivation virale par chauffage a sec selon la temperature de transition vitreuse
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
EP3938742A1 (en) 2019-03-14 2022-01-19 Terumo BCT Biotechnologies, LLC Multi-part lyophilization container and method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100737A (en) * 1958-02-05 1963-08-13 Auerswald Wilhelm Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby
US3041242A (en) * 1958-06-17 1962-06-26 Sr Courtland H Barr Gas and heat sterilization of dried human plasma
DE1617350C3 (de) * 1967-06-22 1979-09-06 Behringwerke Ag, 3550 Marburg Verfahren zur Inaktivierung von biologischem Material
US3859168A (en) * 1967-06-22 1975-01-07 Behringwerke Ag Process of inactivating rabies virus
US3579631A (en) * 1968-05-21 1971-05-18 Aubrey P Stewart Jr Sterilization of materials containing protein
GB1471336A (en) * 1973-04-16 1977-04-21 Armour Pharma Process for the purification and sterilisation of acidophilic biologicals-
US3998516A (en) * 1973-05-15 1976-12-21 Mabuchi Motor Co. Ltd. Adapter
JPS6015B2 (ja) * 1977-07-16 1985-01-05 株式会社新潟鐵工所 水溶性かつ熱凝固性を有する殺菌された血粉の製造方法
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate

Also Published As

Publication number Publication date
AR230186A1 (es) 1984-03-01
IE55008B1 (en) 1990-04-25
FR2526660B1 (fr) 1987-11-20
LU84804A1 (fr) 1983-11-17
FR2526660A1 (fr) 1983-11-18
CA1203165A (en) 1986-04-15
AU569428B2 (en) 1988-01-28
DK210283D0 (da) 1983-05-11
EP0171506B1 (en) 1993-09-22
ES8505821A1 (es) 1985-06-16
EP0094611B1 (en) 1986-06-11
AU5766086A (en) 1986-10-30
ZA833315B (en) 1984-01-25
IE831068L (en) 1983-11-13
DK210283A (da) 1983-11-14
ES8501627A1 (es) 1984-12-01
ATA176783A (de) 1985-10-15
GB2120254A (en) 1983-11-30
DE3382716T2 (de) 1994-03-31
GB8312915D0 (en) 1983-06-15
GB2144428A (en) 1985-03-06
DE3364057D1 (en) 1986-07-17
CH665125A5 (de) 1988-04-29
ES538802A0 (es) 1985-11-01
DK171796B1 (da) 1997-06-02
JPS58213721A (ja) 1983-12-12
ES522310A0 (es) 1984-12-01
AT392905B (de) 1991-07-10
MX172861B (es) 1994-01-17
AU1442183A (en) 1983-12-15
ES535745A0 (es) 1985-06-16
GB8332374D0 (en) 1984-01-11
US4456590B1 (es) 1989-01-03
US4456590B2 (en) 1989-05-30
EP0094611A2 (en) 1983-11-23
GB2120254B (en) 1984-06-20
GB2144428B (en) 1986-03-12
EP0171506A1 (en) 1986-02-19
AU554282B2 (en) 1986-08-14
ES8601701A1 (es) 1985-11-01
AU568979B2 (en) 1988-01-14
US4456590A (en) 1984-06-26
DE171506T1 (de) 1986-11-06
DE3382716D1 (de) 1993-10-28
BR8302504A (pt) 1983-10-25
ES538801A0 (es) 1985-11-01
ES538803A0 (es) 1985-11-01
EP0094611A3 (en) 1984-08-22
AU5765986A (en) 1986-10-09
ES8601699A1 (es) 1985-11-01
BE896724A (fr) 1983-09-01

Similar Documents

Publication Publication Date Title
ES8505821A1 (es) Un metodo de producir una vacuna para la hepatitis
NO864990D0 (no) Solubilisering av proteinaggregater.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
GR79989B (es)
ES8400466A1 (es) Procedimiento para la obtencion de composiciones poliolefinicas.
ATE35905T1 (de) Verfahren zur herstellung keimfreier proteinmischungen.
ZA831451B (en) Process for the preparation of polysaccharide-protein complexes from bacterial capsules,obtained products and immunogenic compositions containing them
DE69132048T2 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
GB8805792D0 (en) Medicaments
DK161366C (da) Fremgangsmaade til inaktivering af formeringsdygtige, filtrerbare sygdomsfremkaldere
DE3166084D1 (en) Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation
ES8503238A1 (es) Procedimiento de preparar concentrados y nutrimentos proteinicos
AU561222B2 (en) Process for the pasteurization of human plasma
CA1337688C (en) Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
GR3014952T3 (en) Use of an immunoglobulin-containing composition in the prophylaxis and therapy of AIDS of human.
EP0158317A3 (en) Biologic and method of preparing same
JPS5557520A (en) Preparation of carcinostatic substance
HU9200701D0 (en) Preparation for pasteurizing blood plasm
AU4811290A (en) A pure factor i protein and a process for producing said protein
Fleischmann Jr et al. [52] Demonstration of potentiation of the antiviral and antitumor actions of interferon
ES8506449A1 (es) Procedimiento para la obtencion de preparados a partir de plasma humano
SU1815820A1 (ru) Способ получения иммуноглобулинового препарата
SU1732518A1 (ru) Способ получения иммуноглобулина м
Baranova et al. Inhibition of transformation of phytohemagglutinin-stimulated lymphocytes by neutral SH-dependent splenic proteinase
SU1476865A1 (ru) Способ получения диалкиловых эфиров протопорфирина-ix

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040604